Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × talazoparib × Endocrine × Clear all

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 7 Genitourinary 6 Gynecologic 4 Gastrointestinal 4 Tumor-Agnostic 2 Sarcoma 2 Other hematologic neoplasm 2 Thoracic 1 Plasma cell 1 NET 1 Myeloid 1 Lymphoid 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 15 Magnetic Resonance Spectroscopy 13 gallium Ga 68 dotatate 8 Specimen Handling 8 Everolimus 8 pembrolizumab 7 Cisplatin 7 cabozantinib 6 Etoposide 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 trametinib 4 lanreotide 4 dabrafenib 4 Fluorodeoxyglucose F18 4 surufatinib 3 olaparib 3 lenvatinib 3 fluorodopa F 18 3 cemiplimab 3 amino-acid, glucose, and electrolyte solution 3 X-Rays 3 Transurethral Resection of Prostate 3 Thyrotropin Alfa 3 Temozolomide 3 Somatostatin 3 Nivolumab 3 Lutetium-177 3 Iodine-131 3 Injections 3 Drug Therapy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡